![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Designates Biological Dynamics’ Pancreatic Cancer Test a Breakthrough Device
FDA Designates Biological Dynamics’ Pancreatic Cancer Test a Breakthrough Device
The FDA has designated Biological Dynamics’ liquid biopsy assay, Exo-PDAC (pancreatic ductal adenocarcinoma), as a breakthrough device.
The assay is designed to detect PDAC, an aggressive and lethal form of cancer early in the course of the disease in high-risk adults.
The assay does this by identifying biomarkers associated with an elevated risk of pancreatic cancer, such as seen in individuals with new-onset diabetes, a family history of pancreatic cancer or certain germline mutations, the company said.
Upcoming Events
-
21Oct